To catch up with the US and Europe, the infant biotechnology industry in Taiwan could leapfrog the expensive and long initial phases of producing a new drug and buy up the rights to projects that have run out of money, a venture capitalist said yesterday.
"Asian biotechnology is five years behind Europe and at least 10 years behind North America," said Don Qiu, director of Asian operations at MDS Capital Corp, which has a US$60 million fund to invest in biotech ventures.
"I favor the Japanese model for Taiwan of cutting into the biotech value chain at any stage through the licensing process," he said.
The process of licensing and bringing a drug to market from research and laboratory trials to clinical trials and official approval can take up to 30 years.
The US started pouring money into drug research early on and now represents three-quarters of the world biotech industry, which totaled US$41 billion last year, figures from Ernst & Young show.
The whole of Asia's biotech industry was worth a mere 3.3 percent of the global total last year, or US$1.4 billion -- even less than Canada's US$1.5 billion. And Asia invested only US$200 million in research in the same period, far short of America's US$16.2 billion.
"Asian countries should spend on research and development, but to catch up, they need to take advantage of the many opportunities out there," Qiu said.
With such a long investment period before profits show -- the industry made a loss of US$12 billion globally last year -- many companies that initially poured their dollars into drugs have run out of money and put projects on hold, leaving a pool of research up for grabs, Qiu said.
Local companies could then prepare the projects for approval, and sell the rights to what is now a Taiwanese brand back to the original owners or other large drug firms at a profit, he added.
Qiu was speaking at a forum in Taipei to bring biotech firms from Canada together with local investors and biotech partners.
"We are hoping to sell our peptide array and find research partners overseas," said forum delegate Connie Tsai (
Others were hoping to outsource some research to Taiwan, or win investments.
One of the organizers agreed that biotech firms have to re-evaluate their investments.
"The days of the technology cycle are over," said Dave Murphy, trade and investment director at the Canadian Trade Office in Taipei.
"It's not feasible to see a two-year turnaround in biotechnology, because tests on human beings are involved. It's a much longer process," he said.
There are other opportunities for Taiwanese firms, Qiu added, that spring from the nation's expertise in information technology and electronics to build medical devices and diagnostic tools.
And Taiwan is also seen as the gateway to the Chinese market. Local biotech companies can buy the rights to market-ready drugs and sell them in Taiwan and China.
The government is promoting biotechnology as one of the advanced industries that can replace Taiwan's shrinking manufacturing base.
"Taiwan's biotech companies need to focus on value, rather than trying to grow to a global size," said David Silver, director of Biotech-east.com, a Web site that promotes Taiwan's biotechnology and pharmaceutical industries, echoing speakers at the international BioBusiness Asia 2003 conference also taking place in Taipei earlier this week.
"If Taiwan, or any other country, wants to go the way of the US and pour lots of money into research, they will still end up a long way behind," he said.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to